Pharmaceuticals & Biotech/Lifesciences
FNArena Windows (Sectors)
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
Latest Stories
Tim Boreham reports cancer treatment biotech Chimeric has struggled, but may yet have a sting in its tail
May 26 2023
Brokers review first quarter results and pending regulatory approvals for Avita Medical
May 17 2023
| ASX CODE | COMPANY NAME | LAST PRICE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET |
|---|---|---|---|---|---|---|
| ACW | $0.05 | $0.16 | $0.04 |
$0.15 |
||
| AFP | AFT PHARMACEUTICALS LIMITED | $3.69 | $3.77 | $2.90 | 29.7 |
$4.00 |
| ANP | ANTISENSE THERAPEUTICS LIMITED | $0.06 | $0.15 | $0.06 |
$0.26 |
|
| ARX | AROA BIOSURGERY LIMITED | $0.94 | $1.25 | $0.63 |
$1.51 |
|
| AVH | AVITA MEDICAL INC | $3.30 | $5.03 | $0.00 |
$5.777 |
|
| CSL | CSL LIMITED | $304.18 | $xx.xx | $xx.xx | xx.x | xx.xx |
| GSS | GENETIC SIGNATURES LIMITED | $0.64 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IMM | IMMUTEP LIMITED | $0.32 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IMU | IMMUTEP LIMITED | $0.11 | $xx.xx | $xx.xx | xx.x | xx.xx |
| KZA | KAZIA THERAPEUTICS LIMITED | $0.18 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MAP | MICROBA LIFE SCIENCES LIMITED | $0.31 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MDC | MEDLAB CLINICAL LIMITED | $6.60 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MSB | MESOBLAST LIMITED | $1.08 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MVP | MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED | $0.72 | $xx.xx | $xx.xx | xx.x | xx.xx |
| NEU | MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED | $13.66 | $xx.xx | $xx.xx | xx.x | xx.xx |
| OCC | MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED | $0.37 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PAR | PARADIGM BIOPHARMACEUTICALS LIMITED | $0.91 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PBP | PROBIOTEC LIMITED | $2.55 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PNV | POLYNOVO LIMITED | $1.55 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PXS | POLYNOVO LIMITED | $0.05 | $xx.xx | $xx.xx | xx.x | xx.xx |
| SPL | STARPHARMA HOLDINGS LIMITED | $0.41 | $xx.xx | $xx.xx | xx.x | xx.xx |
| TLX | TELIX PHARMACEUTICALS LIMITED | $11.83 | $xx.xx | $xx.xx | xx.x | xx.xx |
Previous Stories
Dr Boreham’s Crucible: Radiopharm Theronostics
Apr 13 2023
Cancer detection biotech Radiopharm Theronostics is planning to list on the Nasdaq, and not without good reason, Tim Boreham explains
Dr Boreham’s Crucible: Avita Medical
Mar 29 2023
Tim Boreham highlights the global addressable market opportunity for Avita Medical’s skin graft technology, made famous by the Bali bombings
Telix Pharmaceuticals’ Pipeline Full Of Promise
Mar 21 2023
Following FY22 results for Telix Pharmaceuticals brokers remain Buy-rated in light of an extensive pipeline of new products under development
FDA Approval Puts Rocket Under Neuren Shares
Mar 16 2023
Amidst a sea of red, the Neuren share price has skyrocketed in recent days following a world first approval for the biotech’s treatment of Rett syndrome
Dr Boreham’s Crucible: Actinogen Medical
Nov 30 2022
Actinogen Medical is a biotech with a potentially “gazillion” dollar opportunity in its Alzheimer’s drug
Dr Boreham’s Crucible: Qbiotics Group
Nov 09 2022
Having brought a canine cancer treatment to market, Qbiotic’s focus has returned to treating two-legged cancers including melanoma and other difficult-to-treat cancers
Dr Boreham’s Crucible: Pharmaxis
Oct 05 2022
Pharmaxis might be two clinical studies away from rehabilitation, reports Tim Boreham
Brokers Review Prospects For CSL
Sep 30 2022
Brokers remain generally upbeat on CSL and focus upon the earnings contribution from the Vifor Pharma acquisition
Dr Boreham’s Crucible: Inoviq Ltd
Sep 19 2022
Tim Boreham digs deep into the evolving world of cancer diagnostics, highlighting the newly named Inoviq Ltd
CSL: Offering Buying Opportunity
Sep 13 2022
Michael Gable of Fairmont Equities notes price action suggests CSL is a buying opportunity, and more so on a breakout
Latest News
| 1 |
The Market In Numbers – 27 May 2023May 27 2023 - Australia |
| 2 |
ASX Winners And Losers Of Today – 26-05-23May 26 2023 - Daily Market Reports |
| 3 |
Weekly Top Ten News Stories – 26 May 2023May 26 2023 - Weekly Reports |
| 4 |
Australian Broker Call *Extra* Edition – May 26, 2023May 26 2023 - Daily Market Reports |
| 5 |
Next Week At A Glance – 29 May-2 June 2023May 26 2023 - Weekly Reports |
